The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / Is It Rejection – or Something Else?
Histology Molecular Pathology Biochemistry and molecular biology Clinical care

Is It Rejection – or Something Else?

Combining molecular, histologic, and laboratory findings may support more individualized transplant care

By Jessica Allerton 11/17/2026 Interview 4 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

Clinical Scorecard: Is It Rejection – or Something Else?

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Is It Rejection – or Something Else?
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationKidney transplant recipients evaluated for graft dysfunction or injury
Care SettingCare setting described in the source article.

Key Highlights

  • Biopsy and histology remain central to evaluating graft dysfunction, but biopsy samples only a small part of the organ and findings may be difficult to interpret consistently.
  • Creatinine and estimated glomerular filtration rate indicate kidney function but do not identify the cause of a change.
  • Molecular testing can add information about biological activity in sampled tissue, but does not always establish the cause of injury.
  • Rejection, infection, medication toxicity, reduced blood flow, obstruction, and recurrence of the original disease can cause graft dysfunction and may require different management.
  • Blood- and urine-based biomarkers are being investigated for monitoring and risk assessment; the source does not support their use as universal replacements for biopsy.

Guideline-Based Recommendations

Diagnosis

  • Interpret molecular findings alongside histology, laboratory results, and the patient’s clinical history.
  • Donor-specific antibodies suggest an immune response associated with increased risk, but their presence alone does not confirm active rejection.
  • A rise in creatinine indicates a change in kidney function but does not reveal its cause.

Management

  • Consider the complete diagnostic picture before changing immunosuppressive therapy.
  • Use molecular results as complementary information rather than as a standalone determination of every cause of graft dysfunction.
  • Assess whether molecular testing changes clinical decisions and improves patient outcomes; diagnostic accuracy and clinical benefit are separate questions.

Monitoring & Follow-up

  • Use creatinine and estimated glomerular filtration rate to monitor kidney function and tacrolimus levels to indicate exposure to that medication.
  • The source does not establish a role for tracking molecular measurements over time to guide treatment or medication dosing.
  • Blood- and urine-based biomarkers are being investigated for monitoring and risk assessment; whether they can guide further evaluation or biopsy decisions requires study.

Risks

  • Increasing or changing immunosuppression for presumed rejection could impair control of an infection if infection is driving the injury.
  • Immunosuppressive therapies carry risks including infection, certain cancers, and drug toxicity; risks vary with medication, dose, and treatment duration.
  • Biopsy sampling limitations and variable interpretation can affect assessment; molecular tests do not eliminate these limitations.

Patient & Prescribing Data

Kidney transplant recipients evaluated for graft dysfunction, rejection, or other forms of injury.

Treatment depends on the cause of graft dysfunction. Rejection is often managed by increasing or changing immunosuppression, while infection, medication toxicity, and other causes may require different management. Decisions should integrate molecular results with histology, laboratory findings, and clinical condition.

Clinical Best Practices

  • Use biopsy, laboratory findings, molecular results, and clinical history together when assessing graft injury.
  • Recognize that creatinine, estimated glomerular filtration rate, tacrolimus levels, and donor-specific antibodies address different clinical questions.
  • For molecular test development, use well-characterized samples, clearly defined diagnoses, relevant clinical information, and reference cohorts reflecting the intended population and setting.
  • Assess test performance with independent samples and, ideally, prospective studies.
  • Do not assume that a molecular pattern or test result alone provides a definitive diagnosis.

Related Resources & Content

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.